Ida Vanttinen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Journal: British journal of haematology
Published: March 05, 2026

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Journal: HemaSphere
Published: June 24, 2025

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Journal: Basic & clinical pharmacology & toxicology
Published: November 18, 2024

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Journal: Cancer research
Published: October 15, 2024

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Journal: Blood
Published: April 11, 2024

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.

Journal: Cell death & disease
Published: November 17, 2023

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Journal: Molecular cancer therapeutics
Published: October 19, 2023

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Journal: Haematologica
Published: June 30, 2022

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.

Journal: Blood
Published: February 01, 2021
Showing 1-9 of 9

Last Updated: 09/26/2026